Umbralisib: Treatment for a Rare Lymphoma?

Article Details

Citation

Copy to clipboard

Authors unspecified

Umbralisib: Treatment for a Rare Lymphoma?

Cancer Discov. 2019 Jun;9(6):OF5. doi: 10.1158/2159-8290.CD-NB2019-045. Epub 2019 Apr 1.

PubMed ID

30936084 [ View in PubMed

]

Abstract

The PI3Kdelta inhibitor umbralisib may be a promising therapy for patients with relapsed/refractory marginal zone lymphoma: In the phase IIb UNITY-NHL trial, the drug elicited a response rate of 55%. In addition, patients had a 1-year progression-free survival rate of 71%, with manageable side effects.

DrugBank Data that Cites this Article

Drugs

Umbralisib

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Umbralisib	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Protein	Humans	Yes	Inhibitor	Details